---
figid: PMC7941751__fphar-11-619273-g003
figtitle: Scheme of IL-1R and IL-18 activation, signaling and mechanism of inhibition
organisms:
- NA
pmcid: PMC7941751
filename: fphar-11-619273-g003.jpg
figlink: pmc/articles/PMC7941751/figure/F3/
number: F3
caption: Scheme of IL-1R and IL-18 activation, signaling and mechanism of inhibition.
  (A) IL-1/IL-18 binding cell membrane IL-1R/IL-18 receptors (structure of binary
  complexes), (B) signal transmission via TIR domains, (C) initiation of pro-inflammatory
  response via IRAK-MyD88-TRAF6-TAK1 pathway, activation of transcription factors
  NFkB via IKK and (d-1) AP-1 via JNK-MKK4/7 (MAP kinases) (d-2), (E) IL-1R blockade
  by Anakinra (a recombinant antagonist of the IL-1 receptor , (F) IL-1β inhibition
  by canakinumab and gevokizumab (monoclonal antibodies neutralizing IL-1β), Rilonacept
  (a soluble receptor predominantly binding IL-1β), (G) IL-18 inhibition by Tadekinig
  alfa (a human recombinant IL-18 binding protein) (TIR = Toll/Interleukin-1 Receptor
  domain, MyD88 = Myeloid Differentiation primary response 88, IRAK = Interleukin-1
  Receptor Associated kinase, TRAF6 = TNF Receptor Associated Factor 6, TAK1 = Transforming
  growth factor beta-Activated kinase 1, IKK = NFkB Inhibitor kinase, NFkB = Nuclear
  Factor Kappa B, MAP = Mitogen Activated Protein kinase, JNK = c-Jun N-terminal kinase
  AP1 = Activator Protein 1).
papertitle: 'Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where
  Are We now?.'
reftext: Hana Malcova, et al. Front Pharmacol. 2020;11:619273.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9570874
figid_alias: PMC7941751__F3
figtype: Figure
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
redirect_from: /figures/PMC7941751__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7941751__fphar-11-619273-g003.html
  '@type': Dataset
  description: Scheme of IL-1R and IL-18 activation, signaling and mechanism of inhibition.
    (A) IL-1/IL-18 binding cell membrane IL-1R/IL-18 receptors (structure of binary
    complexes), (B) signal transmission via TIR domains, (C) initiation of pro-inflammatory
    response via IRAK-MyD88-TRAF6-TAK1 pathway, activation of transcription factors
    NFkB via IKK and (d-1) AP-1 via JNK-MKK4/7 (MAP kinases) (d-2), (E) IL-1R blockade
    by Anakinra (a recombinant antagonist of the IL-1 receptor , (F) IL-1β inhibition
    by canakinumab and gevokizumab (monoclonal antibodies neutralizing IL-1β), Rilonacept
    (a soluble receptor predominantly binding IL-1β), (G) IL-18 inhibition by Tadekinig
    alfa (a human recombinant IL-18 binding protein) (TIR = Toll/Interleukin-1 Receptor
    domain, MyD88 = Myeloid Differentiation primary response 88, IRAK = Interleukin-1
    Receptor Associated kinase, TRAF6 = TNF Receptor Associated Factor 6, TAK1 = Transforming
    growth factor beta-Activated kinase 1, IKK = NFkB Inhibitor kinase, NFkB = Nuclear
    Factor Kappa B, MAP = Mitogen Activated Protein kinase, JNK = c-Jun N-terminal
    kinase AP1 = Activator Protein 1).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ADRA1D
  - GPR162
  - IL1R1
  - MYD88
  - IRAK1
  - TRAF6
  - CHUK
  - IKBKB
  - IKBKG
  - IKBKE
  - TBK1
  - MAPK8
  - MAPK9
  - MAPK10
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - FOS
  - FOSB
  - JUN
  - JUNB
  - JUND
  - IL1RAP
  - IL18R1
  - IL18RAP
  - Col4a1
  - Ca-alpha1D
  - alphaTub84B
  - nAChRalpha1
  - wb
  - Prosalpha1
  - Pen
  - alphaTub85E
  - Prosalpha2
  - nAChRalpha2
  - Myd88
  - Traf6
  - IKKepsilon
  - key
  - IKKbeta
  - kk
  - bsk
  - Dif
  - dl
  - Rel
  - AP-1gamma
  - Jra
  - kay
---
